Radioiodide (131I) therapy for the treatment of canine thyroid carcinoma

被引:48
|
作者
Worth, AJ
Zuber, RM
Hocking, M
机构
[1] Massey Univ, Vet Teaching Hosp, Ctr Compan Anim Hlth, Palmerston North, New Zealand
[2] Gladesville Vet Hosp, Gladesville, NSW 2111, Australia
关键词
D O I
10.1111/j.1751-0813.2005.tb11650.x
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Objective To assess the efficacy of radioactive iodine treatment (I-131) for canine thyroid carcinoma, as both the sole therapeutic modality and as an adjunct to surgery. Design Retrospective analysis of case records from the Gladesville Veterinary Hospital Nuclear Medicine Service, Sydney, between August 1988 and December 2001. Case Details The records of 65 dogs with thyroid carcinoma were analysed according to therapy and outcome. Forty-three dogs received radioiodide therapy, either as the sole therapeutic modality (32) or as an adjunct to surgery (11). Radioisotope therapy consisted of one to three doses of I-131 with a dose range of 555 to 1850 MBq. For analysis, dogs were divided into groups according to therapy: no treatment, surgery alone, surgery with radioiodide therapy or radioiodide therapy alone. Mode of therapy, dosage of I-131, clinical staging and age were all independently analysed according to survival to compare efficacy or predictive value respectively. Results When radioiodide therapy was used as an adjunct to surgery, median survival was 34 months. Censored median survival time for dogs that received radioiodide alone was 30 months. Dogs that did not receive treatment had a median survival of only 3 months. Log rank statistical analysis indicated that mode of therapy was significantly correlated with survival but that clinical stage of disease was not. Conclusion The authors conclude that I-131 therapy is effective at extending survival time, both as a sole therapeutic modality and as an adjunct to surgery, in dogs with invasive canine thyroid carcinoma. Incomplete surgical resection may not prolong survival in dogs also receiving I-131 therapy, however surgical resection with curative intent should be recommended as the first line of therapy for mobile thyroid carcinomas. Radioisotope therapy can be recommended for cases where surgery alone is considered unlikely to be curative because of metastatic disease or local invasion, or for cases where surgery has been attempted but complete surgical removal has not been achieved.
引用
收藏
页码:208 / 214
页数:7
相关论文
共 50 条
  • [41] Evaluation of frequency of lung metastases from differentiated thyroid carcinoma and response to 131I therapy
    Kalender, Ebuzer
    Celen, Y. Zeki
    Elboga, Umut
    Demir, Hasan Deniz
    Yilmaz, Mustafa
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [42] Thyroid carcinoma:: metabolic therapy and follow-up with thyroglobulin levels and 131I gammagraphy
    Lampreave, JL
    Trampal, C
    Dominguez, P
    Bittini, A
    REVISTA CLINICA ESPANOLA, 1998, 198 (05): : 307 - 315
  • [43] Clinical features of patients with recurrent or metastatic differentiated thyroid carcinoma after 131I therapy
    蔡晓雨
    China Medical Abstracts(Internal Medicine), 2020, 37 (04) : 205 - 206
  • [44] Efficacy of 131I therapy and its influencing factors in children and adolescents with differentiated thyroid carcinoma
    Luo, Ming
    Hu, Yongjun
    JOURNAL OF BUON, 2021, 26 (03): : 1028 - 1033
  • [45] Prognostic value of serial 131I scans in patinets with differentiated thyroid cancer after 131I therapy.
    Lu, HK
    Zhu, RS
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 410P - 410P
  • [46] Efficacy and Affecting Factors of 131I Thyroid Remnant Ablation After Surgical Treatment of Differentiated Thyroid Carcinoma
    Wang, Chen
    Diao, Hongcui
    Ren, Ping
    Wang, Xufu
    Wang, Yangang
    Zhao, Wenjuan
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [47] Role of 131I in the treatment of well differentiated thyroid cancer
    Woodrum, DT
    Gauger, PG
    JOURNAL OF SURGICAL ONCOLOGY, 2005, 89 (03) : 114 - 121
  • [48] Comparison of methods to estimate maximum permissible administered activity for 131I thyroid carcinoma treatment
    Nichols, Kenneth
    Robeson, William
    Yoshida-Hay, Miyuki
    Palestro, Christopher
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [49] Analysis of the incidence and influencing factors of hyponatremia before 131I treatment of differentiated thyroid carcinoma
    Jing-Jia Cao
    Can-Hua Yun
    Juan Xiao
    Yong Liu
    Wei Wei
    Wei Zhang
    World Journal of Clinical Cases, 2021, (36) : 11173 - 11182
  • [50] The study of influence factors on 131I treatment of differentiated thyroid carcinoma with lymph node metastases
    Ye, Zhi-Yi
    Wang, Hui
    Fu, Hong-Liang
    Li, Jia-Ning
    Zou, Ren-Jian
    Gu, Zhen-Hui
    Wu, Jing-Chuan
    CLINICAL IMAGING, 2009, 33 (03) : 221 - 225